Ibixacin (Ciprofloxacin Hydrochloride Monohydrate)

Ciprofloxacin blocks two essential bacterial enzymes, DNA gyrase and topoisomerase IV. These enzymes are required for DNA replication and transcription. By inhibiting them, ciprofloxacin prevents bacterial DNA from unwinding and replicating, leading to bacterial cell death and resolution of the infection.

The dosage of Ibixacin is determined by the prescribing clinician based on the type and severity of the infection, patient age, weight, renal function and other clinical factors. The prescriber will specify the exact strength, frequency and duration appropriate for each individual case.

The safety of ciprofloxacin in pregnancy and lactation has not been definitively established. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To request Ibixacin, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with other classes such as beta‑lactams, ciprofloxacin offers broad‑spectrum activity against many Gram‑negative and some Gram‑positive organisms, and it achieves high tissue penetration. However, resistance patterns, safety profile and specific pathogen susceptibility guide the choice of antibiotic for each infection.

Ibixacin should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Do not store in bathrooms or near heat sources, and keep the container tightly closed when not in use.

Ibixacin is taken orally, usually as a tablet, with or without food as directed by the prescriber. The tablet should be swallowed whole with a full glass of water, and dosing intervals should be maintained consistently to ensure optimal drug levels.

Serious risks include tendon rupture (especially the Achilles tendon), peripheral neuropathy, severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, QT interval prolongation leading to cardiac arrhythmias, and hepatic injury. Patients should seek immediate medical attention if they experience related symptoms.

Ibixacin is contraindicated in individuals with a known hypersensitivity to ciprofloxacin or other fluoroquinolones. It should also be avoided in patients with a history of tendon disorders related to fluoroquinolone use, and in those for whom safer alternative antibiotics are available, especially during pregnancy unless absolutely necessary.